EMA Authorised: Voydeya (danicopan) — Alexion Europe SAS

View source ↗

Summary

The European Medicines Agency authorised Voydeya (danicopan) for paroxysmal nocturnal hemoglobinuria, designated as an orphan medicine, with marketing authoriza…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Paroxysmal Nocturnal Hemoglobinuria

Drugs mentioned

• VOYDEYA (DANICOPAN)

Snippet

Status: Authorised. Therapeutic area: Hemoglobinuria, Paroxysmal;Hemolysis. MAH: Alexion Europe SAS. Decision date: 12/01/2026. Orphan medicine